ghk cu peptide benefits and side effects GHK-Cu (And a Few Risks) Explained Peptides: What they are, potential

[DOI] [PubMed] [Google Scholar] 231.Seong YJ, Song EH, Park C, Lee H, Kang IG, Kim HE, et al

Most Common Adverse Events Key Observations: Gastrointestinal adverse events are dose-dependent and most pronounced during dose escalation Symptoms typically peak within the first 4-8 weeks and diminish with continued treatment as tolerance develops Slow titration (4-week intervals) significantly reduces the incidence and severity of GI events Most adverse events classified as mild to moderate in severity [9] Discontinuation Rates 7.3% Placebo discontinuation rate [9] 15.8% Cagrilintide 2.4 mg (optimal dose) [9] 24.5% Cagrilintide 4.5 mg (high dose) [9] The majority of discontinuations due to adverse events occurred during the titration phase, with GI symptoms (nausea, vomiting) being the primary reasons

Phase 3 dose levels TRIUMPH-4 tested three dose levels: 4mg, 9mg, and 12mg, all administered once weekly by subcutaneous injection

All prescribing at Peptides Thailand is done on an investigational basis following individual physician assessment of the patient's GI history, current medications, and clinical goals

10.1002/ddr.21163 237 RobbinsJ.SchneiderA